Flamma
成立一年
1950年缺失:Flamma的產品演示和案例研究
促進你的產品提供技術買家。
達到1000年代的買家使用CB的見解來確定供應商,演示產品,188bet游戏做出購買決定。
缺失:Flamma的產品&微分器
不要讓你的產品被跳過。買家使用我們的供應商排名名單公司和驅動(rfp)請求建議。
最新的Flamma新聞
2023年3月20日
項目包括升級現有的分析服務,新設備的安裝,包括反應堆,過濾幹燥器,蒸餾單元。意大利Chignolo Flamma設施03.20.23 Flamma集團全球,充分整合公司生產和商業化小分子活性藥物成分(api)生命科學行業,和CDMO新化學實體(NCEs)和晚期中間體,是投資2億美元在未來三年公司將繼續對市場需求作出回應。•改進和改善Bulciago、意大利網站,於2022年收購了。•完成一個新的GMP工廠在大連,中國的位置。Flamma Honkai會增加小分子API /一旦最初的能力400立方米,最終800立方米。•添加新技術在其網站在意大利、中國和美國o包括越來越多的現有流化學功能Flamma意大利o構建的API潔淨室在美國Flamma o更多改善HPAPI功能Flamma美國•額外的改進將Flamma另外兩個意大利的設施,Chignolo和之。這些網站的改進包括升級現有的分析提供的服務以及新設備的安裝,包括反應堆,過濾幹燥器,蒸餾單元。利用可再生能源,Flamma將增加太陽能電池板。考慮到當前的地緣政治環境,Flamma主動獲取客戶供應鏈的能力從中國轉移項目(Flamma Honkai)意大利(特別是其Bulciago網站)。Flamma市場提供了一個獨特的價值主張在中國還能工作,但也有安全同時也在意大利。 Alternatively, work can be done in China but can be internally transferred to Italy if needed. In addition, the Chinese domestic market will grow dramatically in the coming years and Flamma Honkai’s facilities in China can be the right choice for developing and producing APIs in China for its domestic market. Dr. Gianpaolo Negrisoli, Chief Executive Officer of Flamma, said, “Flamma will continue to reinvest in itself to provide further flexibility among all of our sites.” Flamma Bulciago has reactor capacities up to 25,000 L with an average reactor size of 12,000 L. This GMP site is an attractive option for those companies looking for additional capacities in Europe. The combination of Bulciago along with Chignolo and Isso provides Flamma with 900 m3 of small molecule manufacturing capacity in Italy. The continued development of Flamma USA near Philadelphia, PA provides innovator companies the flexibility to begin early stage small molecule projects in the U.S. and then consider using the rest of the Flamma Group for its needs as the project grows. Since Flamma can often make the necessary RSMs, the security of supply is strengthened by Flamma’s ability to provide internal backup to manufacturing. “Our future is very bright. We are aware of customer sensitivity about their supply chain. Years of work and huge investments have been placed into their molecules. This cannot be jeopardized by looking for the lowest price or underestimating the risks of a weak supply chain. We have manufacturing facilities with different characteristics to meet customer needs. This includes capacity and technologies along with a very skilled and committed team that works hard to be a long-term partner,” said Negrisoli.
Flamma常見問題(FAQ)
Flamma是何時成立的?
Flamma成立於1950年。
Flamma總部在哪裏?
通過Bedeschi Flamma總部位於,22日Chignolo D 'isola。
Flamma的競爭對手是誰?
Flamma的競爭對手包括Kiyatec,預示著生物科學,Foamix製藥、製藥、裏程碑WaferGen就近和12。
比較Flamma競爭對手
固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Optimata有限公司是一個私營企業以科學為基礎的跨學科公司從事biosimulation技術優化藥物治療協議。Optimata與製藥和生物技術公司合作夥伴開發有效的疾病通過模擬疾病新的治療方法流程。這個旨在減少投放市場的時間和開發成本,同時提高競爭力的新開發藥物。
預示腫瘤生物科學是一個公司,專注於評估病人對藥物的臨床試驗。公司使用CIVO技術提供藥物適當濃度的不同地區多個藥物的腫瘤,而腫瘤仍在病人。
公司的核心業務是和仍然是開發和生產的活性藥物成分和腸配方的形式解決方案和凍幹注射,anesthialogy和腫瘤等領域。
RegeneMed公司正在加速的發展更安全、更有效的藥物通過提供集成高通量平台改造人類組織的化驗。RegeneMed擁有專利、專有核心技術使設計的人體組織的體外生長,包括肝髒、胃腸道、骨髓和血腦屏障。這些組織的體外模型係統將加速藥物開發,旨在消除薄弱環節ADME /托克斯評價、藥物製藥行業麵臨失敗的主要原因,每個公司。
Rhenovia製藥是一個法國生物技術公司,成立於2007年由一個國際研究小組彙集了經理從大型製藥公司和世界專家在神經科學和神經係統建模。的公司是一家供應商應用biosimulation在預防和治療神經,神經退行性和精神障礙和疾病。
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。